Dual HER2 Blockade Defers Breast Cancer in CLEOPATRA

feeds has 409 videos Subscribe Here

Description: The addition of pertuzumab to a standard chemotherapy combination of trastuzumab and docetaxel led to an additional 6 months of progression-free survival in patients with HER2-positive metastatic breast cancer, in the CLEOPATRA trial. Dr. José Baselga discusses the potential impact of the findings. See the related story at
Shared By : feeds
Posted on : 12/10/11
Added : 6 years ago
Category : Other

More From feeds

Nothing found.